286 related articles for article (PubMed ID: 7740505)
21. Effects of recombinant human erythropoietin (EPOCH) on the coagulation and fibrinolytic systems and platelet function in pre-dialysis patients with chronic renal failure.
Kaizu K; Uriu K; Eto S
Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):989-97. PubMed ID: 8255011
[TBL] [Abstract][Full Text] [Related]
22. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
el-Shahawy MA; Francis R; Akmal M; Massry SG
Clin Nephrol; 1994 May; 41(5):308-13. PubMed ID: 8050212
[TBL] [Abstract][Full Text] [Related]
24. Prospective double-blind randomized study of the effects of four intravenous fluids on platelet function and hemostasis in elective hip surgery.
Evans PA; Heptinstall S; Crowhurst EC; Davies T; Glenn JR; Madira W; Davidson SJ; Burman JF; Hoskinson J; Stray CM
J Thromb Haemost; 2003 Oct; 1(10):2140-8. PubMed ID: 14521596
[TBL] [Abstract][Full Text] [Related]
25. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients.
Roger SD; Piper J; Tucker B; Raine AE; Baker LR; Kovacs IB
Nephrol Dial Transplant; 1993; 8(3):213-7. PubMed ID: 8385286
[TBL] [Abstract][Full Text] [Related]
26. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients.
Taylor JE; Belch JJ; McLaren M; Henderson IS; Stewart WK
Kidney Int; 1993 Jul; 44(1):182-90. PubMed ID: 8355460
[TBL] [Abstract][Full Text] [Related]
27. Leptin correlates with some hemostatic parameters in CAPD patients.
Małyszko J; Wołczyński S; Małyszko J; Myśliwiec M
Nephron; 2002; 92(3):721-4. PubMed ID: 12372966
[TBL] [Abstract][Full Text] [Related]
28. [Ketanserin decreases erythropoietin concentration in hemodialyzed patients on rHuEPO therapy].
Borawski J; Mazerska M; Pawlak K; Myśliwiec M
Pol Arch Med Wewn; 1994; 92 Spec No():14-20. PubMed ID: 7731894
[TBL] [Abstract][Full Text] [Related]
29. Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patients.
Akizawa T; Kinugasa E; Kitaoka T; Koshikawa S
Nephron; 1991; 58(4):400-6. PubMed ID: 1922603
[TBL] [Abstract][Full Text] [Related]
30. [Effects of the treatment with human recombinant erythropoietin on primary hemostasis in uremic patients].
Cases A; Escolar G; Reverter JC; Garrido M; Ordinas A; López-Pedret J; Castillo R; Revert L
Med Clin (Barc); 1990 Nov; 95(17):644-7. PubMed ID: 2089202
[TBL] [Abstract][Full Text] [Related]
31. Effects of long-term treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal dialysis patients.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Am J Nephrol; 2001; 21(5):373-7. PubMed ID: 11684797
[TBL] [Abstract][Full Text] [Related]
32. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors.
Biesma DH; Bronkhorst PJ; de Groot PG; van de Wiel A; Kraaijenhagen RJ; Marx JJ
J Lab Clin Med; 1994 Jul; 124(1):42-7. PubMed ID: 8035101
[TBL] [Abstract][Full Text] [Related]
33. One-year experience of very low doses of subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis and its effect on haemostasis.
Huraib S; Gader AM; al-Momen AK; Abu-Aisha H; al-Wakeel J; Memon NA
Haemostasis; 1995; 25(6):299-304. PubMed ID: 8586321
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
[TBL] [Abstract][Full Text] [Related]
35. Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats.
Soni HM; Vekaria AM; Rath AC; Belemkar S; Jain MR
Indian J Pharmacol; 2014; 46(3):328-33. PubMed ID: 24987182
[TBL] [Abstract][Full Text] [Related]
36. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients.
Borawski J; Pawlak K; Myśliwiec M
Nephron; 2002 Aug; 91(4):671-81. PubMed ID: 12138272
[TBL] [Abstract][Full Text] [Related]
38. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen.
Beguin Y; Loo M; R'Zik S; Sautois B; Lejeune F; Rorive G; Fillet G
Blood; 1993 Oct; 82(7):2010-6. PubMed ID: 8400253
[TBL] [Abstract][Full Text] [Related]
39. Sex differences in the platelet response to aspirin.
Coppe D; Wessinger SJ; Ransil BJ; Harris W; Salzman E
Thromb Res; 1981 Jul 1-15; 23(1-2):1-21. PubMed ID: 7302916
[No Abstract] [Full Text] [Related]
40. The hemostatic system.
Stassen JM; Arnout J; Deckmyn H
Curr Med Chem; 2004 Sep; 11(17):2245-60. PubMed ID: 15379710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
